help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bookman, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bookman, M. A.
The Oncologist, Vol. 4, No. 2, 87-94, April 1999
© 1999 AlphaMed Press

Extending the Platinum-Free Interval in Recurrent Ovarian Cancer: The Role of Topotecan in Second-Line Chemotherapy

Michael A. Bookman

Medical Gynecologic Oncology, Medical Information Management, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA

Correspondence: Michael A. Bookman, M.D., Medical Gynecologic Oncology, Medical Information Management, Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, Pennsylvania, 19111 USA. Telephone: 215-728-2987; Fax: 215-728-3639; e-mail: ma_bookman{at}fccc.edu

Although the combination of platinum and paclitaxel offers effective chemotherapy for advanced ovarian cancer, the majority of women will eventually relapse with development of drug-resistant disease. Topotecan is the most extensively studied agent currently available for management of recurrent ovarian cancer and has been approved by the FDA for that particular indication. Early use of topotecan offers an effective and tolerable strategy that can prolong the platinum-free interval and optimize subsequent retreatment with platinum.

Key Words. Platinum-free interval (PFI) • Ovarian cancer • Topotecan • Relapsed or recurrent disease • Second-line chemotherapy




This article has been cited by other articles:


Home page
 Ann OncolHome page
J. M. Del Campo, A. Roszak, M. Bidzinski, T. E. Ciuleanu, T. Hogberg, M. Z. Wojtukiewicz, A. Poveda, K. Boman, A. M. Westermann, C. Lebedinsky, et al.
Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer
Ann. Onc., November 1, 2009; 20(11): 1794 - 1802.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. W. ten Bokkel Huinink, J. Sufliarsky, W. M. Smit, S. Spanik, M. Wagnerova, H. W. Hirte, S. Kaye, A. R. Johri, and A. M. Oza
Safety and Efficacy of Patupilone in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer: A Phase I, Open-Label, Dose-Escalation Study
J. Clin. Oncol., July 1, 2009; 27(19): 3097 - 3103.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Sehouli, D. Stengel, G. Oskay-Oezcelik, A. G. Zeimet, H. Sommer, P. Klare, M. Stauch, A. Paulenz, O. Camara, E. Keil, et al.
Nonplatinum Topotecan Combinations Versus Topotecan Alone for Recurrent Ovarian Cancer: Results of a Phase III Study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
J. Clin. Oncol., July 1, 2008; 26(19): 3176 - 3182.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. A. Cannistra
Is There a "Best" Choice of Second-Line Agent in the Treatment of Recurrent, Potentially Platinum-Sensitive Ovarian Cancer?
J. Clin. Oncol., March 1, 2002; 20(5): 1158 - 1160.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 1999 by AlphaMed Press.